Navigation Links
Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
Date:12/30/2011

AMSTERDAM, December 30, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Company has raised € 2.5 million in new equity by means of a private placement to three of its existing shareholders: Forbion Capital Partners, Gilde Healthcare Partners and Advent Venture Partners.

Under the terms of the transaction, AMT has agreed to issue 7,352,938 new shares at a price of € 0.34 per share, being the closing price on December 29, 2011, when the shares were placed. The proceeds of this issue will provide additional flexibility to further explore its strategic options to secure the financial stability of the Company. The proceeds do not eliminate the Company's negative equity position, which will continue after completion of the equity raising, which is expected to take place on or around January 4, 2012, and the Company's financial prospects remain as described in the announcement of December 15, 2011.

As a result of the private placement, the Company's issued share capital will amount to 31,051,454 shares.

Pursuant to the Financial Supervision Act (Wet op het financieel toezicht) there is no obligation to publish a prospectus approved by the Netherlands Authority for the Financial Markets (Autoriteit Financiele Markten) in relation to the equity raising or the admission of the new shares to trading on NYSE Euronext in Amsterdam. The Netherlands Authority for the Financial Markets does not supervise the equity raising or the admission of the new shares to trading on NYSE Euronext in Amsterdam.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

 

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 



'/>"/>
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics Announces Negative Equity Position
2. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
3. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
4. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
5. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
7. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... , ... February 03, 2016 , ... ... Linux and Unix visualization solutions today announced the addition of a powerful “Session ... users to see the current state of the remote Linux desktop or other ...
(Date:2/3/2016)... Therapeutics, Inc., today announced the closing of a $6 million ... total of $10.25 million in Series A funding based on ... was led by existing investor The Kraft Group of ... Lear Corporation and Highland Consumer Partners, as well as existing ... Sackler , MD, with Summer Road, LLC; Erin Donohue ...
(Date:2/3/2016)... , ... February 03, 2016 , ... ... to aid in the rapid development and ongoing quality control of molecular assays ... outbreak is extremely high,” Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix, ...
(Date:2/3/2016)... ... 03, 2016 , ... Marktech Optoelectronics, a leading supplier of ... epi wafers based in Latham, New York, offers a wide variety of ... Si and InGaAs PIN photodiodes. But it is Marktech's newly enhanced capability to ...
Breaking Biology Technology:
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
(Date:2/2/2016)... Feb. 2, 2016   Parabon NanoLabs ... U.S. Army Research Office and the Defense Forensics ... sensitivity of the company,s Snapshot Kinship Inference ... and, more generally, defense-related DNA forensics.  Although Snapshot ... (predicting appearance and ancestry from DNA evidence), it ...
(Date:2/1/2016)... , Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces ... personality, Joey Fatone . Las Vegas , ... --> Las Vegas , where Joey appeared ... The new video ad was filmed at the Consumer Electronics Show ... the Wocket booth to meet and greet fans. ...
Breaking Biology News(10 mins):